GlassScriptPhysician profile
Robert Passovoy
NPI 1841229408
$777.00
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $169.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $240.13 | 2019-2020 | |
| Novo Nordisk INC | $150.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $82.31 | 2019-2020 | |
| Amgen INC. | $61.11 | 2019-2020 | |
| Astellas Pharma US INC | $54.48 | 2019 | |
| Sunovion Pharmaceuticals INC. | $43.89 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $35.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.22 | 2019 | |
| Abbvie INC. | $21.48 | 2020 | |
| Roche Diagnostics Corporation | $18.85 | 2019 | |
| Alfasigma USA, INC. | $16.54 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.12 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.05 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Passovoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.